Return to site Beyond CBD: Why Minor Cannabinoids Are Becoming the Next Big Formulation Trend

For years, the cannabinoid market was built around two familiar names: THC and CBD. That story is changing. Product developers, researchers and consumers are paying closer attention to compounds that naturally occur in smaller concentrations in the cannabis plant. These minor cannabinoids include CBN, CBC, THCV, CBDV, CBGA and several lesser-known molecules entering product development.

The trend is not simply about finding another fashionable ingredient. It reflects a shift toward purpose-led cannabinoid formulations. Instead of placing one large dose of CBD into every product, brands are exploring measured combinations designed for different formats, occasions and consumer preferences.

Why Interest Is Growing Now

Minor cannabinoids have been known for years, but obtaining them at scale was once difficult and expensive. Improved cultivation, extraction, conversion, purification and analytical testing have made these compounds more accessible to formulators.

Scientific attention is also expanding. A 2026 review mapping the research landscape found growing interest in CBG, CBN and CBC, while concluding that the evidence remains fragmented. That combination—commercial curiosity alongside research gaps—is one reason the category is moving quickly but still requires responsible communication.

Consumers are another part of the change. Many understand the difference between full-spectrum, broad-spectrum and isolate products. They now read labels more carefully, compare cannabinoid ratios and look beyond total CBD content. As product knowledge improves, a label featuring CBC, CBN or THCV no longer appears as unfamiliar as it once did.

From General Wellness to Targeted Formulas

The biggest trend surrounding minor cannabinoids is “functional” formulation. In practical terms, this means building a product around a defined use occasion rather than making broad promises.

CBN is commonly associated in the marketplace with evening products. THCV is frequently used in daytime or energy-positioned concepts. CBC may be added to balanced multi-cannabinoid blends, while CBDV and CBGA are attracting attention from research-led developers. These positions should not be confused with proven medical outcomes. Human evidence for many minor cannabinoids is still limited, and marketing claims must reflect the law and available science.

For brands, the opportunity lies in creating a more understandable product experience. A formula may combine a familiar base cannabinoid with a smaller amount of a secondary cannabinoid, supported by suitable terpenes, carrier oils or other permitted ingredients. The result has a clearer identity than another generic “CBD oil.”

Why Isolates Matter to Product Developers

High-purity isolates give formulators tighter control over what goes into a finished product. This is useful when a company wants repeatable ratios, less variation between batches or the ability to study one cannabinoid without the complexity of a whole-plant extract.

Using a measured isolate can also help with flavour, colour and formulation stability. Botanical extracts may carry strong aromas, pigments, waxes or other components unsuitable for certain products. A well-characterised isolate offers a cleaner starting point, although the final formulation still requires compatibility, stability and safety testing.

Businesses exploring minor cannabinoids should look beyond the cannabinoid name. Purity, residual-solvent results, cannabinoid profile, contaminant testing, production consistency and documentation are equally important. A cheaper ingredient can become costly if its specifications vary or the supplier cannot provide adequate batch records.

Quality Documentation Is a Competitive Advantage

As the market matures, buyers are asking harder questions. A certificate of analysis should identify the tested batch and show more than a headline purity percentage. Depending on the material and intended use, buyers may also need information about residual solvents, pesticides, heavy metals, microbiology and stability.

Identity testing matters as well. Some cannabinoids have similar chemical structures, and emerging compounds can be difficult to distinguish without appropriate analytical methods. Reliable sourcing therefore depends on qualified laboratories, traceable production and specifications matching the finished-product requirements.

Documentation helps separate dependable ingredients from poorly characterised powders sold through hype. Brands will compete not only through unusual cannabinoid combinations but also through transparency and consistency.

European Compliance Cannot Be an Afterthought

Interest in minor cannabinoids does not mean every ingredient can automatically be used in every product. In the European Union, cannabinoid status can depend on the compound, manufacturing method, concentration, product category, claims and country of sale.

Before launching, businesses should verify the legal position for the exact cannabinoid and application. They should also review labelling, advertising, age restrictions, THC limits, product safety and cross-border shipping requirements. Regulatory planning is easier before packaging and inventory have been produced.

What Comes Next for Minor Cannabinoids?

The next phase will probably be defined by smarter combinations rather than a race to launch the rarest molecule. Successful products will use cannabinoids that can be sourced consistently, formulated safely and explained without exaggerated claims.

Research may eventually clarify which compounds and ratios are most useful for particular applications. Until then, brands can still innovate by focusing on quality, responsible positioning and consumer education.

Minor cannabinoids are moving from the edge of the industry toward the centre of product development. Their long-term value will not come from novelty alone. It will come from turning complex plant chemistry into reliable, transparent and products that customers can understand.